Canada Consults On Disclosing Names Of Generic Drug Applicants
Executive Summary
Health Canada currently does not disclose the names of the companies that have filed abbreviated new drug submissions and it wants to know what the possible impacts of doing so are.
You may also be interested in...
Australia Considers Identifying Drugs Filed For Approval
The Therapeutic Goods Administration wants to know whether, and how, it should disclose the fact that a medicine has been accepted for regulatory review. It has put several options to stakeholders, including disclosure for all medicines or only certain kinds, or keeping the current practice of “neither confirm nor deny.”
New Canadian Transparency Drive To Facilitate Better Planning For Industry
Health Canada is making its decision-making process in the pre-market phase more transparent by disclosing a wider range of information on new and generic drug applications accepted for review.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.